CEBP Meeting Calendar Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Locke, I.
Right arrow Articles by Eeles, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Locke, I.
Right arrow Articles by Eeles, R. A.
Cancer Epidemiology Biomarkers & Prevention Vol. 15, 1399-1402, July 2006
© 2006 American Association for Cancer Research


Short Communication

Loss of Heterozygosity at the BRCA1 and BRCA2 Loci Detected in Ductal Lavage Fluid from BRCA Gene Mutation Carriers and Controls

Imogen Locke1,2, Zsofia Kote-Jarai1,2, Elizabeth Bancroft1,2, Sarah Bullock1, Sarah Jugurnauth1, Peter Osin1,2, Ashutosh Nerurkar2, Louise Izatt3, Gabriella Pichert3, Gerald P. H. Gui1,2 and Rosalind A. Eeles1,2

1 The Institute of Cancer Research; 2 The Royal Marsden NHS Foundation Trust; and 3 Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

Requests for reprints: Imogen Locke, Department of Cancer Genetics, The Royal Marsden NHS Foundation Trust, Orchard House, Downs Road, Sutton, Surrey SM2 5PT, United Kingdom. Phone: 44-20-8661-3105; Fax: 44-20-8770-1489. E-mail: imogen.locke{at}icr.ac.uk

Female BRCA gene mutation carriers are at increased risk for developing breast cancer. Ductal lavage is a novel method for sampling breast ductal fluid, providing epithelial cells for cytologic assessment and a source of free DNA for molecular analyses. Loss of heterozygosity (LOH) at the BRCA loci in ductal lavage fluid is a potential biomarker of breast cancer risk. The LOH rate was measured at the BRCA1/2 loci and compared with that at a control locus (APC) using free DNA from the ductal lavage fluid of BRCA carriers and predictive test negative controls. We evaluated the reproducibility of these analyses. Free DNA sufficient for PCR amplification was obtained from 33 ductal lavage samples of 17 healthy women of known BRCA status (14 BRCA carriers and 3 controls). LOH rates of 36.4% to 56.3% at the BRCA1 locus and 45% to 61.5% at the BRCA2 locus were found among BRCA carriers. The LOH rate at the APC locus was lower (18.5%). The interaliquot reproducibility for the D17S855 marker of the BRCA1 locus was 66.7%. Intraaliquot reproducibility was 90%. Although we successfully isolated sufficient free DNA from ductal lavage fluid for PCR amplification, the degree of reproducibility of these LOH studies raises questions about the robustness of this technique as a risk assessment tool in the evaluation of high-risk women. Further studies are required to evaluate the specificity and predictive value of LOH in ductal lavage fluid for breast cancer development. (Cancer Epidemiol Biomarkers Prev 2006;15(7):1399–402)







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.